enzalutamide (Xtandi)

following an independent review panel

enzalutamide (Xtandi®) is accepted for use within NHS Scotland.

Indication under review: Treatment of adult men with metastatic castration-resistant prostate cancer (mCRPC) who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated.

In a randomised, double-blind phase III study of adult men with chemotherapy naive mCRPC treatment with enzalutamide was associated with a statistically significant extended overall survival and radiographic progression free survival compared to placebo.

This advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of enzalutamide. This advice is contingent upon the continuing availability of the patient access scheme in NHS Scotland or a list price that is equivalent or lower.

This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.